menu
    • menu
    [{"orgOrder":0,"company":"iQure Pharma","sponsor":"Avance Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"iQ-007","moa":"EAAT2","graph1":"Neurology","graph2":"Phase I","graph3":"iQure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iQure Pharma \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"iQure Pharma \/ Avance Clinical"},{"orgOrder":0,"company":"iQure Pharma","sponsor":"Keiretsu Mid-Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Series A Financing","leadProduct":"iQ-007","moa":"EAAT2","graph1":"Neurology","graph2":"Preclinical","graph3":"iQure Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iQure Pharma \/ Keiretsu Mid-Atlantic","highestDevelopmentStatusID":"4","companyTruncated":"iQure Pharma \/ Keiretsu Mid-Atlantic"}]

    Find Clinical Drug Pipeline Developments & Deals by iQure Pharma

    Menu

    iQure Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            iQure Pharma

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            iQure Pharma

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : iQ-007

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Avance Clinical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of IQ-007

                            Details : IQ-007 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Drug Resistant Epilepsy.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 27, 2025

                            Lead Product(s) : iQ-007

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Avance Clinical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            iQure Pharma

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            iQure Pharma

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : iQ-007

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Keiretsu Mid-Atlantic

                            Deal Size : $0.6 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            iQure Pharma Secures $600K in Early Closing to Research Neuropathic Pain Therapies

                            Details : The preclinical development of iQure's novel therapeutics iQ-007 and iQ-008. In addition, both compounds are supported by non-dilutive funding through the NIH epilepsy (ETSP) and NIH pain (PSPP) programs.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 31, 2022

                            Lead Product(s) : iQ-007

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Keiretsu Mid-Atlantic

                            Deal Size : $0.6 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth